The online version of this article (doi:10.1186/s12885-017-3207-7) contains supplementary material, which is available to authorized users.
Accurate prognosticating is needed when patients are nearing the end of life to ensure appropriate treatment decisions, and facilitate palliative care provision and transitioning to terminal care. People with a hematological malignancy characteristically experience a fluctuating illness trajectory leading to difficulties with prognosticating. The aim of this review was to identify current knowledge regarding ‘bedside’ prognostic factors in the final 3 months of life for people with a hematological malignancy associated with increased risk of mortality.
A systematic review of the literature was performed across: PubMed; CINAHL; PsycINFO; and Cochrane with set inclusion criteria: 1) prognostic cohort studies; 2) published 2004–2014; 3) sample ≥ 18 years; 4) >50% sample had a hematological malignancy; 5) reported ‘bedside’ prognostic factors; 6) median survival of <3 months; and 7) English language. Quality appraisal was performed using the Quality In Prognostic Studies (QUIPS) tool. Results are reported in line with PRISMA guidelines.
The search returned 4860 studies of which 28 met inclusion criteria. Twenty-four studies were rated moderate quality, three were high quality and one study was deemed to be of low quality. Most studies were set in the ICU (n = 24/28) and were retrospective (n = 25/28). Forty ‘bedside’ prognostic factors were identified as associated with increased risk of mortality encompassing the following broad categories: 1) demographics; 2) physiological complications or conditions; 3) disease characteristics; 4) laboratory blood values; and 5) interventions.
The literature on prognosticating in the final months of life was predominantly focused on people who had experienced acute physiological deterioration and were being treated aggressively in the in-patient setting. A significant gap in the literature exists for people who are treated less aggressively or are on a palliative trajectory. Findings did not report on, or confirm the significance of, many of the key prognostic factors associated with increased risk of mortality at the end of life in the solid tumour population, demonstrating key differences in the two populations.
This systematic review was not registered.
Additional file 1: Prognostic factors identified as associated with mortality. In Additional file 1, the findings for each prognostic factor are displayed for each study. If a prognostic factor was tested in a study, the results are reported for that factor (i.e. if the factor was significant and the direction of association). It is also recorded if results were not reported. (DOCX 29 kb)12885_2017_3207_MOESM1_ESM.docx
Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol. 2007;18(1):3–8. CrossRef
Pallister C, Watson M. Haematology. 2nd ed. Banbury: Scion Publishing Limited; 2011.
Hung Y-S, et al. Characteristics of patients with hematologic malignancies who received palliative care consultation services in a medical center. Am J Hosp Palliat Med. 2013;30(8):773–80. CrossRef
McGrath P. Palliative care for patients with haematological malignancies: if not, why not? J Palliat Care. 1999;15:24–30. PubMed
WHO. WHO definition of palliative care. 2012. http://www.who.int/cancer/palliative/definition/en/. Cited 28 June 2013.
NICE. Improving outcomes in haematological cancers. The manual. London: National Institute for Clinical Excellence; 2003.
Dalgaard K, Thorsell G, Delmar C. Identifying transitions in terminal illness trajectories: a critical factor in hospital-based palliative care. International Journal of Palliative Medicine. 2010;16(2):87–92.
Christakis N. Death foretold: prophecy and prognosis in medical care. Chicago: University of Chicago Press; 1999.
ASCO. Clinical cancer advances 2016. 2016. https://www.asco.org/research-progress/reports-studies/clinical-cancer-advances#/message-ascos-president-0. Cited 7 Dec 2016.
Highet G, et al. Development and evaluation of the Supportive and palliative care indicators tool (SPICT): a mixed method study. Supportive and Palliative Care. 2013;1:1–6.
Innes, S. and S. Payne, Advanced cancer patients’ prognostic information preferences: a review. Palliative medicine . 2008.
Steinhauser KE, et al. Preparing for the end of life: preferences of patients, families, physicians, and other care providers. J Pain Symptom Manag. 2001;22(3):727–37. CrossRef
Moher D, et al. Preferred reporting items for systematic reviews and meta analyses: The PRISMA statement. PLoS Med. 2009;6(6):e10000097.
NHMRC. How to review the evidence: systematic identification and review of the scientific literature. Canberra: Commonwealth of Australia; 2000.
Higgins JPT and Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated march 2011]. 2011, The Cochrane Collaboration, 2011.
Altman D. Systematic reviews of evaluations of prognostic variables. Br Med J. 2001;323:224–8. CrossRef
Sauerbrei, W. and D. Altman. Challenges in design, analysis and reporting of prognostic and predictive marker research – from single studies to an EBM based assessment. Cochrane Colloquium: Germany; 2008.
Nishida K, Palalay MP. Prognostic factors and utility of scoring systems in patients with hematological malignancies admitted to the intensive care unit and required a mechanical ventilator. Hawaii Med J. 2008;67(10):264–9. PubMed
Owczuk R, et al. Patients with haematological malignancies requiring invasive mechanical ventilation: differences between survivors and non-survivors in intensive care unit. Supportive Care Cancer. 2005;13:332–8. CrossRef
Park MR, et al. Outcomes in critically ill patients with hematologic malignancies who received renal replacement therapy for acute kidney injury in an intensive care unit. J Crit Care. 2011;26(1):107.e1–6. CrossRef
Price KJ, et al. Prognostic indicators of mortality of mechanically ventilated patients with acute leukemia in a comprehensive cancer center. Minerva Anestesiol. 2013;79(2):147–55. PubMed
des Ordons ALR, et al. Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: a case-control study. Bio Medical Central Cancer. 2010;10(1):516.
Ferra C, et al. Lack of impact of human immunodeficiency virus infection on the outcome of lymphoma patients transferred to the intensive care unit. Leuk Lymphoma. 2012;53(10):1966–70. CrossRef
Ferra C, et al. Outcome and prognostic factors in patients with hematologic malignancies admitted to the intensive care unit: a single-center experience. Int J Hematol. 2006;85(3):195–202. CrossRef
Hampshire PA, et al. Admission factors associated with hospital mortality in patients with haematological malignancy admitted to UK adult, general critical care units: a secondary analysis of the ICNARC case mix programme database. Crit Care. 2009;13(4):1–17. CrossRef
BaHammam AS, et al. Outcome of patients with hematological malignancies admitted to the intensive care unit with life-threatening complications. Saudi Med. J. 2005;26(2):246–50.
Polit D, Beck C. Nursing research: generating and assessing evidence for nursing practice. 9th ed. China: Lippincott Williams & Wilkins; 2012.
Field AP. Discovering statistics using IBM SPSS statistics : and sex and drugs and rock ‘n’ roll. London: Sage Publications; 2013.
Hulley SB, et al. Designing clinical research. Philadelphia: Lippincott Williams & Wilkins; 2013.
Williams, K. and C. Moon, An introduction to systematic reviews of prognosis, in For the Chochrane Prognosis Review Methods Group. 2010.
Soares M, et al. Short-and long-term outcomes of critically ill patients with cancer and prolonged ICU length of stay. CHEST Journal. 2008;134(3):520–6. CrossRef
Murray SA, et al. In: Sallnow L, Kumar S, Kellehear S, editors. Illness trajectories and palliative care, in International perspectives on public health and palliative care. New York: Routledge; 2013. p. 30–51.
Chou WC, Kao CY, Wang PN, et al. The application of the palliative prognostic index, charlson comorbidity index, and Glasgow prognostic score in predicting the life expectancy of patients with hematologic malignancies under palliative care. BMC Palliative Care. 2015;14(18):1–7.
Murray SA, et al. Illness trajectories and palliative care. Br Med J. 2005;330(7498):1007–11. CrossRef
Tamburini M, et al. Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manag. 1996;11(1):32–41. CrossRef
Chow E, et al. How accurate are physicians’ clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review. Clin Oncol. 2001;13(3):209–18.
Cheng BHW, et al. Intensive palliative care for patients with hematological cancer dying in hospice: analysis of the level of medical care in the final week of life. American Journal of Hospice and Palliative Medicine. 2015:1–5.
Brück P, et al. Dying of hematologic patients—treatment characteristics in a German University hospital. Supportive Care Cancer. 2012;20:2895–902. CrossRef
Button E, et al. Signs, symptoms, and characteristics associated with end of life in people with a hematologic malignancy: a review of the literature. Oncol Nurs Forum. 2016;43(5):178–87. CrossRef
Department of Health. End of life care strategy for England: promoting high quality care for all adults at the end of life. London: Department of Health; 2008.
The Scottish Government. Living and dying well: building on progress. Edinburgh: The Scottish Government; 2011.
Gold Standards Framework. Prognostic Indicator Guidance. 2011. http://www.goldstandardsframework.org.uk. Cited 19 May 2014.
Temel JS, et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic nonsmall-cell lung cancer: Results of a randomized study of early palliative care. J. Clin. Oncol. 2011;29(17):2319-2326.
Loggers, E., et al., Advance care planning among hematopoietic cell transplant patients and bereaved caregivers . Bone Marrow Transplantation, 2014.
Cartoni C, et al. Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience. Leukemia & lymphoma. 2009;50(3):387–91. CrossRef
- A systematic review of prognostic factors at the end of life for people with a hematological malignancy
Raymond Javan Chan
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II